Marwa Monier Mahmoud Refaie (Marwa M M Refaie)

Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 13

Top Topics

Inflammatory Response

Nitric Oxide Synthase

Signaling Pathway

Top Venues

Cardiovascular toxicology

The Journal of pharmacy and pharmacology

Fundamental & clinical pharmacology

Immunopharmacology and immunotoxicology

This page only lists publications with an associated author ORCID identifier.

Publications

Marwa Monier Mahmoud Refaie, Entesar Farghly Amin, Marwa Nadi Hassan, Rehab Ahmed Rifaai, Asmaa M A Bayoumi, Maha Yehia Kamel
Sacubitril/valsartan protective effect on induced intestinal ischemia/reperfusion injury via immune modulation of IL6/STAT1 pathway. The Journal of pharmacy and pharmacology 76 (7) (2024)
Marwa Monier Mahmoud Refaie, Entesar Farghly Amin, Marwa Nadi Hassan, Rehab Ahmed Rifaai, Asmaa M A Bayoumi, Maha Yehia Kamel
Sacubitril/valsartan protective effect on induced intestinal ischemia/reperfusion injury via immune modulation of IL6/STAT1 pathway. The Journal of pharmacy and pharmacology (2024)
Marwa Monier Mahmoud Refaie, Rehab Ahmed Rifaai, Michael Atef Fawzy, Sayed Shehata
Retraction Note: Dapagliflozin Guards Against Cadmium-Induced Cardiotoxicity via Modulation of IL6/STAT3 and TLR2/TNFα Signaling Pathways. Cardiovascular toxicology (2023)
Marwa Monier Mahmoud Refaie, Manar Fouli Gaber Ibrahim, Michael Atef Fawzy, Elshymaa A Abdel-Hakeem, Eman Shaaban Mahmoud Abd El Rahman, Nagwa M Zenhom, Sayed Shehata
Molecular mechanisms mediate roflumilast protective effect against isoprenaline-induced myocardial injury. Immunopharmacology and immunotoxicology (2023)
Marwa Monier Mahmoud Refaie, Rehab Ahmed Rifaai, Asmaa M A Bayoumi, Sayed Shehata
Sacubitril/valsartan cardioprotective effect against cisplatin-induced cardiotoxicity via modulation of VEGF/eNOS and TLR4/TNFα/IL6 signalling pathways. The Journal of pharmacy and pharmacology (2023)
Marwa Monier Mahmoud Refaie, Maram El-Hussieny, Sayed Shehata
TLR4/NF-κB/TNFα and cAMP/SIRT1 signaling cascade involved in mediating the dose-dependent effect of cilostazol in ovarian ischemia reperfusion-induced injury. Immunopharmacology and immunotoxicology 44 (3) (2022)
Marwa Monier Mahmoud Refaie, Rehab Ahmed Rifaai, Michael Atef Fawzy, Sayed Shehata
Dapagliflozin Guards Against Cadmium-Induced Cardiotoxicity via Modulation of IL6/STAT3 and TLR2/TNFα Signaling Pathways. Cardiovascular toxicology 22 (10-11) (2022)
Ashraf A Aly, Alaa A Hassan, Maysa M Makhlouf, Mohammed B Alshammari, Sara Mohamed Naguib Abdel Hafez, Marwa Monier Mahmoud Refaie, Stefan Bräse, Martin Nieger, Mohamed Ramadan
Design and synthesis of hydrazinecarbothioamide sulfones as potential antihyperglycemic agents. Archiv der Pharmazie 354 (5) (2021)
Marwa Monier Mahmoud Refaie, Sayed Shehata, Asmaa M A Bayoumi, Nashwa Fathy Gamal El-Tahawy, Walaa Yehia Abdelzaher
The IL-6/STAT Signaling Pathway and PPARα Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity. Cardiovascular drugs and therapy (2021)
Marwa Monier Mahmoud Refaie, Sayed Shehata, Randa Ahmed Ibrahim, Asmaa M A Bayoumi, Seham A Abdel-Gaber
Dose-Dependent Cardioprotective Effect of Hemin in Doxorubicin-Induced Cardiotoxicity Via Nrf-2/HO-1 and TLR-5/NF-κB/TNF-α Signaling Pathways. Cardiovascular toxicology 21 (12) (2021)
Marwa Monier Mahmoud Refaie, Sayed Shehata, Maram El-Hussieny, Wedad M Abdelraheem, Asmaa M A Bayoumi
Role of ATP-Sensitive Potassium Channel (KATP) and eNOS in Mediating the Protective Effect of Nicorandil in Cyclophosphamide-Induced Cardiotoxicity. Cardiovascular toxicology 20 (1) (2020)
Marwa Monier Mahmoud Refaie, Rehab A Rifaai, Asmaa M A Bayoumi, Sayed Shehata
Cardioprotective effect of hemin in isoprenaline-induced myocardial infarction: role of ATP-sensitive potassium channel and endothelial nitric oxide synthase. Fundamental & clinical pharmacology 34 (3) (2020)
Marwa Monier Mahmoud Refaie, Rehab A Rifaai, Nagwa M Zenhom
Role of PPAR-α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats. Fundamental & clinical pharmacology 32 (6) (2018)